Latest NewsOvaprene phase 3 interim data supports potential of monthly hormone-free contraceptive ChaseMay 20, 2026 Daré Bioscience has announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial (NCT06127199) of Ovaprene, an investigational monthly, hormone-free intravaginal contraceptive. ContraceptionHealthcareReproductive rightsUnited States
